In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives
OXA-48 producers displayed high susceptibility to cefepime-enmetazobactam, which is similar to ceftazidime-avibactam, including for OXA-48 producers that coproduce a ceftazidime hydrolyzing enzyme (extended-spectrum β-lactamases or AmpC). In vivo experiments have to be implemented to confirm if cefepime-enmetazobactam might be a relevant alternative to ceftazidime-avibactam for the treatment of infections caused by OXA-48 producers.
Authors
- Katy Jeannot
- Juan Quevedo
- Laurent Dortet (ORCID: https://orcid.org/0000-0001-6596-7384)
- Rémy A. Bonnin (ORCID: https://orcid.org/0000-0002-2307-3232)
- Anne Santerre Henriksen (ORCID: https://orcid.org/0000-0002-7294-6386)
Institutions
- Inserm (FR)
- Advantest (Singapore) (SG)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- CEA Paris-Saclay (FR)
- CNR de la Résistance aux Antibiotiques (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1016/j.cmi.2024.09.031
- Citations
- 39
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 6.64
Funders
- Cardiome Pharma Corp.